Advertisement

Intensive BP, Lipid Lowering Does Not Protect Against Cognitive Decline in Diabetics — Physician’s First Watch

Medical News |
February 4, 2014

Intensive BP, Lipid Lowering Does Not Protect Against Cognitive Decline in Diabetics

By Amy Orciari Herman

Intensive treatment of blood pressure or cholesterol does not slow the rate of cognitive decline in adults with type 2 diabetes, according to a substudy of the ACCORD trial published in JAMA Internal Medicine.

Some 3000 older adults with poorly controlled diabetes, high cardiovascular risk, and no evidence of cognitive impairment were assigned to one of two study arms: in one, participants were randomized to either intensive BP lowering (systolic goal, <120 mm Hg) or standard BP therapy (goal, <140 mm Hg); in the other, participants with LDL levels controlled below 100 mg/dL on simvastatin were randomized to either additional therapy with fenofibrate or placebo.

At 40 months, cognitive scores had decreased in all groups, with no difference between intensive and standard BP treatment nor between fibrate and placebo.

The researchers conclude that these results, along with previous ACCORD findings, "make clear the decreasing returns of intensive medication-based therapy" for advanced type 2 diabetes.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement